Pharmacological distribution diagram for β-catenin inhibitors obtained using the DF4 (the black color represents β-catenin inhibitors and the white color, the compounds without β-catenin inhibition activity).

Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream targets of inhibitors.

Elisabeth A. Boström (495490)
Elin Kindstedt (779601)
Rima Sulniute (776997)
Py Palmqvist (779602)
Mirjam Majster (779603)
Cecilia Koskinen Holm (776996)
Stephanie Zwicker (779604)
Reuben Clark (779605)
Sebastian Önell (779606)
Ingegerd Johansson (7760)
Ulf H. Lerner (779607)
Pernilla Lundberg (61743)

August 2015

Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream t...

Biophysical survey of small-molecule β-catenin inhibitors: A cautionary tale

McCoy, Michael, Arron
Spicer, Dominique
Wells, Neil J.
Hoogewijs, Kurt
Fiedler, Marc
Baud, Matthias G.J.

May 2022

The canonical Wingless-related integration site signaling pathway plays a critical role in human phy...

Treatment distribution for the 296 inferred drugs that neither have cancer as the original indication nor in clinical trials for cancer.

Luis Tari (148566)
Nguyen Vo (148572)
Shanshan Liang (148578)
Jagruti Patel (148582)
Chitta Baral (148584)
James Cai (377406)

July 2012

Treatment distribution for the 296 inferred drugs that neither have cancer as the original indica...

Pharmacological distribution diagram for natural β-catenin inhibitors obtained using the DF3 (the black color represents natural β-catenin inhibitors and the white color, the compounds without β-catenin inhibition activity).

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Pharmacological distribution diagram for natural β-catenin inhibitors obtained using the DF3...

Pharmacological distribution diagram for Akt inhibitors obtained using the DF2 (the black colour represents Akt inhibitors and the white colour, the compounds without Akt inhibition activity).

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Pharmacological distribution diagram for Akt inhibitors obtained using the DF2 (the <i...

Pharmacological distribution diagram for natural Akt inhibitors obtained using the DF1 (the black colour represents Akt inhibitors and the white colour, the compounds without Akt inhibition activity).

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Pharmacological distribution diagram for natural Akt inhibitors obtained using the DF1...

Distribution of tested inhibitors across the kinome.

Matthew Ryals (516790)
Kwang Pak (405682)
Rahul Jalota (4524190)
Arwa Kurabi (344167)
Allen F. Ryan (405683)

October 2017

The inhibitor targets are indicated in red. The kinome diagram is adapted, with permission, from ...

Shape-based pharmacophore model of the inhibition of Vivid® CYP3A4 green activity by ginsenosides.

Miao Hao (50690)
Yuqing Zhao (50691)
Peizhan Chen (50692)
He Huang (50693)
Hong Liu (50694)
Hualiang Jiang (19452)
Ruiwen Zhang (50695)
Hui Wang (30400)

February 2013

The model was generated from the 3D structure of PPT and its activities against CYP3A4. PPT fitte...

Scheme of Akt and β-catenin inhibitors research through Molecular Topology by virtual screening on SPECS databases.

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Scheme of Akt and β-catenin inhibitors research through Molecular Topology by virtual screening o...

Selection of compounds fitted into the pharmacophore.

Wibke S. U. Roland (550037)
Marijn P. A. Sanders (697041)
Leo van Buren (550041)
Robin J. Gouka (550038)
Harry Gruppen (550039)
Jean-Paul Vincken (550043)
Tina Ritschel (697042)

March 2015

A) Fitting of agonist kaempferol (gray) into the pharmacophore features 0, 3...

Identification of CGK062 as a potent small-molecule inhibitor of Wnt/β-catenin pathway.

Jungsug Gwak (129513)
Jee-Hyun Lee (129516)
Young-Hwa Chung (129517)
Gyu-Yong Song (129518)
Sangtaek Oh (129520)

October 2012

(A) Screening of compounds that inhibit the Wnt/β-catenin pathway. Compounds modulating TOPFlash ...

Potency distribution profiles of 88 and 650 anticancer drugs and natural products.

Chu Qin (115759)
Kai Leng Tan (115760)
Cun Long Zhang (115763)
Chun Yan Tan (115766)
Yu Zong Chen (113383)
Yu Yang Jiang (115770)

November 2012

Potency distribution profiles of 88 and 650 anticancer drugs and natural products.</p

Schematic diagram of avibactam inhibition and deacylation pathways of KPC-2.

Nikhil P. Krishnan (792291)
Nhu Q. Nguyen (792292)
Krisztina M. Papp-Wallace (792293)
Robert A. Bonomo (188763)
Focco van den Akker (158508)

September 2015

Schematic diagram of avibactam inhibition and deacylation pathways of KPC-2.</p

Figure illustrating the structure-activity relationship for the antimicrobial activity of benzophenanthridine alkaloids.

Luciana de C. Tavares (563319)
Graciane Zanon (563320)
Andréia D. Weber (563321)
Alexandre T. Neto (563322)
Clarice P. Mostardeiro (563323)
Ivana B. M. Da Cruz (563324)
Raul M. Oliveira (563325)
Vinicius Ilha (563326)
Ionara I. Dalcol (563327)
Ademir F. Morel (563328)

May 2014

Figure illustrating the structure-activity relationship for the antimicrobial activity of benzoph...

Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies.

Strobl, G.R.
von Kruedener, S.
Stöckigt, J.H.H.
Guengerich, F.P.
Wolff, T.

January 1993

To gain insight into the specificity of cytochrome P-450 2D6 toward inhibitors, a preliminary pharma...

Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream targets of inhibitors.

Elisabeth A. Boström (495490)
Elin Kindstedt (779601)
Rima Sulniute (776997)
Py Palmqvist (779602)
Mirjam Majster (779603)
Cecilia Koskinen Holm (776996)
Stephanie Zwicker (779604)
Reuben Clark (779605)
Sebastian Önell (779606)
Ingegerd Johansson (7760)
Ulf H. Lerner (779607)
Pernilla Lundberg (61743)

August 2015

Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream t...

Biophysical survey of small-molecule β-catenin inhibitors: A cautionary tale

McCoy, Michael, Arron
Spicer, Dominique
Wells, Neil J.
Hoogewijs, Kurt
Fiedler, Marc
Baud, Matthias G.J.

May 2022

The canonical Wingless-related integration site signaling pathway plays a critical role in human phy...

Treatment distribution for the 296 inferred drugs that neither have cancer as the original indication nor in clinical trials for cancer.

Luis Tari (148566)
Nguyen Vo (148572)
Shanshan Liang (148578)
Jagruti Patel (148582)
Chitta Baral (148584)
James Cai (377406)

July 2012

Treatment distribution for the 296 inferred drugs that neither have cancer as the original indica...

Pharmacological distribution diagram for natural β-catenin inhibitors obtained using the DF3 (the black color represents natural β-catenin inhibitors and the white color, the compounds without β-catenin inhibition activity).

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Pharmacological distribution diagram for natural β-catenin inhibitors obtained using the DF3...

Pharmacological distribution diagram for Akt inhibitors obtained using the DF2 (the black colour represents Akt inhibitors and the white colour, the compounds without Akt inhibition activity).

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Pharmacological distribution diagram for Akt inhibitors obtained using the DF2 (the <i...

Pharmacological distribution diagram for natural Akt inhibitors obtained using the DF1 (the black colour represents Akt inhibitors and the white colour, the compounds without Akt inhibition activity).

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Pharmacological distribution diagram for natural Akt inhibitors obtained using the DF1...

Distribution of tested inhibitors across the kinome.

Matthew Ryals (516790)
Kwang Pak (405682)
Rahul Jalota (4524190)
Arwa Kurabi (344167)
Allen F. Ryan (405683)

October 2017

The inhibitor targets are indicated in red. The kinome diagram is adapted, with permission, from ...

Shape-based pharmacophore model of the inhibition of Vivid® CYP3A4 green activity by ginsenosides.

Miao Hao (50690)
Yuqing Zhao (50691)
Peizhan Chen (50692)
He Huang (50693)
Hong Liu (50694)
Hualiang Jiang (19452)
Ruiwen Zhang (50695)
Hui Wang (30400)

February 2013

The model was generated from the 3D structure of PPT and its activities against CYP3A4. PPT fitte...

Scheme of Akt and β-catenin inhibitors research through Molecular Topology by virtual screening on SPECS databases.

Riccardo Zanni (729628)
Maria Galvez-Llompart (729629)
Cecilia Morell (729630)
Nieves Rodríguez-Henche (729631)
Inés Díaz-Laviada (729632)
Maria Carmen Recio-Iglesias (729633)
Ramon Garcia-Domenech (729634)
Jorge Galvez (543448)

April 2015

Scheme of Akt and β-catenin inhibitors research through Molecular Topology by virtual screening o...

Selection of compounds fitted into the pharmacophore.

Wibke S. U. Roland (550037)
Marijn P. A. Sanders (697041)
Leo van Buren (550041)
Robin J. Gouka (550038)
Harry Gruppen (550039)
Jean-Paul Vincken (550043)
Tina Ritschel (697042)

March 2015

A) Fitting of agonist kaempferol (gray) into the pharmacophore features 0, 3...

Identification of CGK062 as a potent small-molecule inhibitor of Wnt/β-catenin pathway.

Jungsug Gwak (129513)
Jee-Hyun Lee (129516)
Young-Hwa Chung (129517)
Gyu-Yong Song (129518)
Sangtaek Oh (129520)

October 2012

(A) Screening of compounds that inhibit the Wnt/β-catenin pathway. Compounds modulating TOPFlash ...

Potency distribution profiles of 88 and 650 anticancer drugs and natural products.

Chu Qin (115759)
Kai Leng Tan (115760)
Cun Long Zhang (115763)
Chun Yan Tan (115766)
Yu Zong Chen (113383)
Yu Yang Jiang (115770)

November 2012

Potency distribution profiles of 88 and 650 anticancer drugs and natural products.</p

Schematic diagram of avibactam inhibition and deacylation pathways of KPC-2.

Nikhil P. Krishnan (792291)
Nhu Q. Nguyen (792292)
Krisztina M. Papp-Wallace (792293)
Robert A. Bonomo (188763)
Focco van den Akker (158508)

September 2015

Schematic diagram of avibactam inhibition and deacylation pathways of KPC-2.</p

Figure illustrating the structure-activity relationship for the antimicrobial activity of benzophenanthridine alkaloids.

Luciana de C. Tavares (563319)
Graciane Zanon (563320)
Andréia D. Weber (563321)
Alexandre T. Neto (563322)
Clarice P. Mostardeiro (563323)
Ivana B. M. Da Cruz (563324)
Raul M. Oliveira (563325)
Vinicius Ilha (563326)
Ionara I. Dalcol (563327)
Ademir F. Morel (563328)

May 2014

Figure illustrating the structure-activity relationship for the antimicrobial activity of benzoph...

Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies.

Strobl, G.R.
von Kruedener, S.
Stöckigt, J.H.H.
Guengerich, F.P.
Wolff, T.

January 1993

To gain insight into the specificity of cytochrome P-450 2D6 toward inhibitors, a preliminary pharma...

Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream targets of inhibitors.

Elisabeth A. Boström (495490)
Elin Kindstedt (779601)
Rima Sulniute (776997)
Py Palmqvist (779602)
Mirjam Majster (779603)
Cecilia Koskinen Holm (776996)
Stephanie Zwicker (779604)
Reuben Clark (779605)
Sebastian Önell (779606)
Ingegerd Johansson (7760)
Ulf H. Lerner (779607)
Pernilla Lundberg (61743)

August 2015

Schematic figure of the canonical versus non-canonical NF-κB signaling pathways, and downstream t...

Biophysical survey of small-molecule β-catenin inhibitors: A cautionary tale

McCoy, Michael, Arron
Spicer, Dominique
Wells, Neil J.
Hoogewijs, Kurt
Fiedler, Marc
Baud, Matthias G.J.

May 2022

The canonical Wingless-related integration site signaling pathway plays a critical role in human phy...

Treatment distribution for the 296 inferred drugs that neither have cancer as the original indication nor in clinical trials for cancer.

Luis Tari (148566)
Nguyen Vo (148572)
Shanshan Liang (148578)
Jagruti Patel (148582)
Chitta Baral (148584)
James Cai (377406)

July 2012

Treatment distribution for the 296 inferred drugs that neither have cancer as the original indica...

Pharmacological distribution diagram for β-catenin inhibitors obtained using the DF<sub>4</sub> (the <i>black color</i> represents β-catenin inhibitors and the <i>white color</i>, the compounds without β-catenin inhibition activity).

Abstract

Extracted data

Pharmacological distribution diagram for β-catenin inhibitors obtained using the DF<sub>4</sub> (the <i>black color</i> represents β-catenin inhibitors and the <i>white color</i>, the compounds without β-catenin inhibition activity).

Abstract

Extracted data

Related items

Related items